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Metformin therapy, severity and mortality 
of SARS-CoV-2 infection: a meta-analysis
AbSTRACT
background. It has been postulated that metformin 
could have anti-SARS-CoV-2 action. This raises the 
hypothesis that people who take metformin may have 
lower SARS-CoV-2 severity and/or mortality. 
Objectives. To conduct a meta-analysis of the associa-
tion between the use of Metformin and risk of severity 
and mortality in SARS-CoV-2 infection. 
Methods. we searched PubMed, EMbASE, google 
scholar, the Cochrane Database of Systematic Reviews 
and preprint servers (medRxiv and Research Square) for 
studies published between December 2019 and Janu-
ary 2021. Data was extracted on study location, year 
of publication, design, number of participants, sex, 
age at baseline, body mass index, and exposure and 
outcome definition. Effect statistics were pooled using 
random effects models with 95% confidence intervals 
(CI). The quality of included studies was assessed with 
the newcastle-Ottawa Scale (nOS).
Results. Thirty-two observational studies were includ-
ed, combining to a total sample of 44306 participants. 
The mean nOS score of included studies was 7.9. 
Results suggested that metformin use was associated 
with a reduced risk of SARS-CoV-2 mortality (OR = 0.56, 
95% CI: 0.46–0.68, P < 0.001; 22 studies) but not 
with disease severity (OR = 0.85, 95% CI: 0.71–1.02, 
P = 0.077; 15 studies). In the subgroup analysis, met-
formin reduces the risk of mortality (OR = 0.69, 95% CI: 
0.55–0.88; P = 0.002) and severity (OR = 0.83, 95% CI: 
0.70–0.97, P = 0.023) in patients aged 70 and above.
Conclusions. The use of metformin was associated 
to lower risk of mortality from SARS-CoV-2 infection. 
This association does not imply causation and further 
research is required to clarify potential mechanisms. 
(Clin Diabetol 2021; 10; 4: 317–329)
Key words: SARS-CoV-2 infection, COVID-19, 
metformin, mortality, type 2 diabetes
Introduction
Metformin (dimethyl biguanide) roots from the 
medieval European herbal medicine (Galega officinalis, 
French lilac), rich in guanidine and was used in patients 
with influenza [1–3]. Metformin is a guanidine deriva-
tive synthesized in the 1920s and approved by the FDA 
in 1994 and since 2009 is the first-line oral treatment 
for type 2 diabetes mellitus (T2DM) according to the 
ADA (American Diabetes Association) and EASD ( Euro-
pean Association for the Study of Diabetes) [4].
At the liver level, metformin inhibits the mitochon-
drial respiratory chain, activating AMP protein kinase 
(AMPK) and improving insulin sensitivity through 
effects on fat metabolism; additionally, it decreases 
cAMP, thus reducing the expression of gluconeogenic 
enzymes. Furthermore, metformin inhibits fructose-1,6-
bisphosphatase by a hepatic AMPK-independent 
mechanism [2].
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SARS-CoV-2 uses angiotensin-converting enzyme 2 
(ACE2) as a receptor to enter the human cell, through the 
interaction of its spike proteins (S1) with the N-terminal 
region of ACE2. As part of the process, the RBD-PD com-
plex is formed, made up of the receptor binding domain 
(RBD) of the virus bound to the PD (the protease domain) 
of the human ACE2 receptor [5]. It has been postulated 
that in the pathophysiology of the acute lung injury 
(ALI) caused by SARS-CoV-2, ACE2 is involved through 
autophagy linked to the AMPK/mTOR pathway [6]. In 
animal studies, AMPK has been shown to increase ACE2 
expression and stability by phosphorylation of ACE2 [6]. 
It has been hypothesized that by acting on AMPK, 
metformin may reduce the inflow of SARS-CoV-2 to 
the cell and avoid downregulation of ACE2 receptors 
caused by the virus [7]. Previous studies in animal 
models have shown that metformin may have immu-
nomodulatory, antiviral and preventive activity against 
acute lung injury [8, 9]. In the context of the current 
COVID-19 pandemic, it is not known if humans with 
type 2 diabetes who use metformin may have protec-
tion against adverse outcomes from SARS-CoV-2 infec-
tion. Hence, the present systematic review investigated 
the association between previous use of Metformin 
in diabetic patients and mortality and severity from 
SARS-CoV-2 infection.
Methods
This study was conducted following the guidelines 
of the Preferred Reporting Items for Systematic Reviews 
and Meta-analyses (PRISMA) [10].
Search strategy 
Two independent investigators performed a sys-
tematic review in PubMed, EMBASE, Google scholar, the 
Cochrane Database of Systematic Reviews and preprint 
servers (medRxiv and Research Square) for studies pub-
lished between December 2019 and January 2021. The 
full search strategy can be seen in Appendix 1. 
Eligibility criteria 
The inclusion criteria for the studies were: rand-
omized controlled trials (RCTs) or observational studies 
reporting data on Metformin and risk of SARS-CoV-2 
infection mortality and/or severity. We included stud-
ies in English (all ages) that presented data on hazard 
ratios (HRs), relative risks (RRs), or odds ratios (ORs) 
with confidence intervals (CIs) or offered enough data 
to allow those to be calculated.
Quality assessment
The quality of observational studies (cohort and 
case control studies) and RCTs were appraised accord-
ing to the Newcastle-Ottawa Quality Assessment Scale 
(NOS) [11] and the Cochrane Risk of Bias Assessment 
Tool [12] respectively. Two investigators evaluated the 
quality of the studies independently. Conflicting results 
were resolved by discussion and involvement of a third 
reviewer if necessary. 
Data extraction 
The following data were extracted from each study: 
authors, study location, year of publication, study 
design, number of participants, sex, age at baseline, 
outcome definition, exposure definition, body mass 
index (BMI) and effect estimates and 95% CIs.
Statistical analyses
Statistical analyses 
Primary analyses evaluated the association 
(hazard ratios, relative risks or odds ratios) between 
metformin and risk of mortality in SARS-CoV-2 in-
fection. We used the random effects model with an 
inverse variance method to calculate the pooled RRs 
and 95% CIs according to the heterogeneity between 
studies [13]. In order to calculate the effect size of 
metformin and risk of severity of in SARS-CoV-2 infec-
tion, the relative risk or odds ratio published by the 
authors of the included studies were used. The overall 
estimates in the pooled analysis were obtained using 
Stata 13 software (Stata Corp LP, College Station, 
TX). Subgroups analyses were performed according 
to mean age and BMI.
Results
Characteristics of included studies 
The flowchart of included studies is detailed in 
Figure 1. Out of 946 potentially relevant articles, and 
following application of inclusion criteria, 32 studies 
were retained including a total of 44306 participants. 
The included studies were conducted in Austria [14], 
Belgium [15], China [16–24], France [25–27], Hong 
Kong [28], Iraq [29], Italy [30, 31], Russia [32]which 
determines the high relevance of risk factor analysis for 
outcomes in DM patients to substantiate the strategy 
for this category of patients. AIM: To assess the effect 
of clinical and demographic parameters (age, gender, 
body mass index (BMI, South Korea [33, 34], Spain [35, 
36], UK [37–41] and USA [42–45]. 
In terms of study design, 18 were case-control, 12 
cohort, and 2 cross-sectional studies. Across studies, 
mean age was 66.7 + 5.3 years and 54.8% were men. 
The mean BMI was 27.5 + 2.8 (13 studies). The mean 
NOS score of included studies was 7.9 (range: 7–9). 
The full characteristics of included studies are detailed 
in Table 1.
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Studies included (n = 32)
Additional records identied through 
EMBASE, Google Scholar and other 
sources (n = 901)
Records screened (abstracts) 
(n = 62)
Record sRecords screened (abstracts) 
(n = 62)
Records excluded (abstracts) 
(n = 17)
Full-text articles assessed for eligibility 
(n = 46)
Records identied though 

































Full-text articles excludes, with reasons (n = 16)
• Reviews (12)
• No data to calculate mortality or severity (4)
Figure 1. Study screening flowchart
Metformin and risk of mortality  
in SARS-CoV-2 infection 
As shown in Figure 2, Metformin use was associ-
ated with reduced risk of mortality (OR = 0.56, 95% 
CI: 0.46–0.68, P < 0.001; 22 studies)
Metformin and risk of severe SARS-CoV-2 infection
The severity criteria of the included studies (15) 
were intensive care unit (ICU) admission (7 studies), 
acute respiratory distress syndrome (2), mechanical 
ventilation (3), and CT image / ICU admission / me-
chanical ventilation (3) (Table 1). And as shown in 
Figure 3, metformin was not significantly associated 
with disease severity (OR = 0.85, 95% CI: 0.71–1.02, 
P = 0.077; 15 studies). 
Metformin and risk of mortality and severe 
(composite endpoint) SARS-CoV-2 infection
Three studies analyzed composite endpoint 
(mortality and severity) [27, 28, 40] and metformin 
was not significantly associated with disease sever-
ity and mortality (OR = 0.82, 95% CI: 0.44–1.53, 
P = 0.025).
Age and bMI subanalyses
In the subgroup analysis, metformin reduces 
the risk of mortality (OR = 0.69, 95% CI: 0.55–0.88; 
P = 0.002) and severity (OR = 0.83, 95% CI: 0.70–0.97, 
P = 0.023) in patients aged 70 and above. In studies 
with a predominance of male, metformin reduces 
the risk of mortality (OR = 0.62, 95% CI: 0.50–0.77; 
P < 0.001) and severity (OR = 0.84, 95% CI: 0.73–0.97; 
P = 0.016). In the studies that reported BMI, appar-
ently the decrease in mortality was greater in those 
with BMI > 30 compared to those with BMI < 30 (OR 
= 0.49, 95% CI: 0.41–0.58 vs. OR = 0.30, 95% CI: 
0.17–0.54); there were no severity studies with BMI 
> 30. The sub-analysis by sex was not done, because 
the studies did not report their results separately, except 
for one study [44].
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Interleukin-6 (Il-6) levels 
Only 2 studies measured the serum concentration 
of IL-2 in patients with or without metformin [16, 30], 
Figure 2. Forest plot of the Metformin and risk of mortality in SARS-CoV-2 infection. Analysis model: random effect. OR: odds 
ratio; CI: confidence interval
Figure 3. Forest plot of the Metformin and risk of severity in SARS-CoV-2 infection. Analysis model: random effect. OR: odds 
ratio; CI: confidence interval
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Discussion
The present study found that the previous use of 
metformin in patients with type 2 diabetes is associated 
with lower risk of mortality from SARS-CoV-2 infection 
but not with disease severity. However, it should be 
noted that this association does not imply causality. In 
the subgroup analysis, we found a decrease in the risk 
of mortality and severity in those over 70 years of age. 
Additionally, some studies found that previous use of 
metformin in diabetic patients could be related to lower 
levels of IL-6 during COVID-19 infection. 
Prior to this study, four meta-analytic studies were 
published with similar findings, although with fewer 
studies and without severity data [46–49]. On the 
other hand, before the COVID-19 pandemic, Liang et 
al. [50] published a meta-analytical study that found 
that the use of metformin prior to hospitalization for 
septic shock may reduce mortality in diabetic patients. 
Using data from the Coronavirus SARS-CoV-2 and 
Diabetes Outcomes (CORONADO) study, Lalau et al. 
[27] found that metformin was associated with a re-
duction in a composite endpoint (tracheal intubation 
for mechanical ventilation and/or death), and death by 
day 28, but linked to increased severity on admission 
regarding clinical, radiological, and biological features, 
compared with metformin non-users. The most likely 
explanation for this apparently discordant finding is 
that hospitalized patients who use metformin tend to 
be more multimorbid at baseline, rather than develop 
a more severe illness due to taking metformin. However, 
a hypothesis was proposed that the time lag between 
the onset of COVID-19 symptoms and hospital admis-
sion was significantly longer in metformin users, and 
the rate of dyspnoea, a major severity criterion, was 
not more frequent in metformin users [27]. 
In the subgroup analysis, we found that metformin 
users had decreased risk of mortality and severity in 
patients with an age equal to or older than 70 years; 
this finding could be interesting because according 
to a recent meta-analyzes on 59 studies showed that 
patients aged 70 and above have a higher risk for 
COVID-19 infection, severe disease, ICU admission 
and death [51]. The probable mechanism by which 
metformin reduces mortality and severity in patients 
older than 70 years would be through its action at 
the level of mitochondrial function. It is known that 
decline in mitochondrial function occurs with aging 
and may increase mortality; on the other hand, in the 
pathophysiology of SARS-CoV-2 infection there is the 
hypothesis that mitochondrial function is compro-
mised, specifically the complex interaction of innate 
immune function, viral replication, hyperinflammatory 
state, and HIF-a / sirtuin pathways (hypoxia-inducible 
transcription factors, HIF) [52]. Currently there is 
enormous interest in drugs called “inflammaging or 
geroprotectors”, so called because they are molecules 
which can target chronic inflammation associated with 
aging, obesity, and metabolic syndrome [53]. One of 
these inflammaging drugs, or geroprotectors, is met-
formin, because it activates 5’AMP-activated protein 
kinase (AMPK) and inhibits the mTOR pathway, may 
improve metabolic derangements, improve mitochon-
drial function, and decrease cytokine production [54]. 
Recently Bharath et al. [55] demonstrated in vitro that 
metformin improves autophagy and mitochondria in 
parallel to decrease inflammaging. The findings of the 
present study regarding a probable protective effect in 
the male sex require more studies, because the included 
studies did not report the respective analysis separately 
by gender, and the division between studies with a male 
or female predominance may be debatable. However, 
these results are published to be taken into account in 
the design of future studies.
At the biological level, there could be possible 
mechanisms associated with metformin-associated 
antiviral, immunomodulatory and preventive activity 
for acute lung injury. In this regard, the relationship 
between glucose metabolism and viral replication have, 
in the past few years, started to be the object of thor-
ough investigation, starting from HIV-1 [56, 57]. The 
antiviral activity of metformin has been demonstrated 
in dengue virus infection, by restoring AMPK activity 
in early stages of infection [58], in animal models with 
Coxsackievirus B3 (CVB3) infection [59], and Kaposi 
sarcoma herpesvirus [60]. It has been postulated that 
Table 2. Association between use of Metformin and mor-
tality and severity of SARS-CoV-2 infection — summary of 
subgroup analyses
Subgroup Studies (n) Adjusted OR (95% CI) P
Age
Mortality*
< 70 12 0.43 (0.30–0.61) < 0.001
≥ 70 8 0.69 (0.55–0.88) 0.002
Severity
< 70 12 0.84 (0.64–1.11) 0.221
≥70 3 0.83 (0.70–0.97) 0.023
BMI
Mortality
< 30 6 0.49 (0.41–0.58) < 0.001
≥ 30 2 0.30 (0.17–0.54) < 0.001
Severity
< 30 5 0.91 (0.77–1.08) 0.291
≥ 30 0
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the anti-COVID-19 activity of metformin may be due 
to interference in the interaction of the ACE2 recep-
tor and SARS-CoV-2, through its action on AMPK [7, 
61]. At the level of human endothelial cells, AMPK 
phosphorylates ACE2 Ser680 and increases ACE2 
expression by enhancing its stability. Metformin also 
enhances the phosphorylation and expression of ACE2 
[28]. Phosphorylation produces a conformational and 
functional ACE2 receptor and decreases the binding 
of SARS-CoV-2, thus interfering with the entry of the 
virus into the human cell [7, 61]. There is the hypoth-
esis that Metformin could negatively alter endocytosis, 
maturation of endosomes, and transport of virions 
to the replication site [62], producing an endosomal 
alkaline environment, due to its direct action on the 
eNHEs (Na+/H+ exchangers) and/or the V-ATPase, 
two membrane compartments for the maintenance 
and regulation of endosomal acidic pH [63–65]. This 
mechanism would thus be similar to that of a widely 
studied investigational anti-SARS-CoV-2 agent, i.e. hy-
droxychloroquine, which however gave controversial 
results in vivo [66, 67]. 
Metformin may have immunomodulatory activity 
because it reduces the production of pro-inflammatory 
cytokines using macrophages, causes the formation 
of neutrophil extracellular traps (NETs) and inhibits 
the production of cytokines from pathogenic Th1 and 
Th17 cells; therefore, it could potentially suppress the 
cytokine storm produced by severe COVID-19 [68]. 
Experimental studies in animal models have shown that 
metformin has an action against lung injury [69–72]. A 
recent study using bovine pulmonary artery endothelial 
cells (BPAEC), showed that metformin enhanced the 
vascular barrier integrity, since it produces an increase 
in the transendothelial resistance of endothelial mon-
olayers [73]. Additionally, metformin may attenuate 
lung injury caused by the high pressure of mechanical 
ventilation [74].
Two studies included in this meta-analysis found 
significantly lower levels of IL-6 in diabetic patients 
with COVID-19 taking metformin compared to those 
who did not use it [16, 30]. In this regard, before the 
COVID-19 pandemic, it was known that multiple my-
eloma patients treated with metformin had significantly 
lower levels of IL-6R expression and promoted apop-
tosis of myeloma cells [75]. The use of metformin in 
patients with polycystic ovary syndrome reduces serum 
levels of IL-6 and improves chronic inflammation [76]. 
Metformin can also reduce IL-6 secretion by alveolar 
macrophages and reduce pulmonary thrombosis in 
mice [77]. Additionally, metformin can inhibit the 
IL-6 signaling pathway, thus overcoming the acquired 
resistance of lung cancer to epidermal growth factor 
receptor tyrosine kinase inhibitors [78]. There is, there-
fore, increasing interest in metformin as a potential 
therapeutic agent in COVID-19 infection [79]. 
Discontinuation of metformin has been recom-
mended in patients with severe COVID-19 infection due 
to the potential risk of lactic acidosis [80]. However, in 
a study that included 1212 hospitalized patients with 
COVID-19 and pre-existing diabetes, Cheng et al. [18] 
found that metformin was associated with the inci-
dence of acidosis, but not with an increase in mortality 
associated with COVID-19. On the contrary, metformin 
was associated with a significant decrease in heart 
failure and inflammation, but acidosis and kidney func-
tion should be carefully monitored in individuals with 
severe COVID-19 [18]. One study reported that 29% of 
patients hospitalized for COVID-19 continued to take 
metformin and lactic acidosis was not reported[81]. In 
clinical practice, metformin is generally suspended im-
mediately after the patient is admitted in a severe state, 
to avoid lactic acidosis. It is possible that metformin has 
an effect after having been suspended, in this regard it 
is known that it appears to accumulate in erythrocytes, 
and after its suspension it remains detectable in eryth-
rocytes up to 48 hours [82], so it takes nearly one week 
for total elimination of metformin from the body [83].
The present study has limitations derived from the 
design of the included studies, which are observational 
and some were preprints (4/32) and not clinical tri-
als. Most of the included observational studies were 
retrospective cohorts and potential selection bias of 
patients is an indisputable concern. On the other hand, 
in the interpretation of the analysis of their groups, 
caution should be taken because few studies reported 
data on BMI. 
 In conclusion the present study found that the 
previous use of metformin in patients with type 2 dia-
betes is associated with a lower risk of mortality from 
SARS-CoV-2 infection, but not severity. This associa-
tion does not imply causation and further research is 
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We searched the NCBI and Medline databases for potentially eligible records.
The search terms were as follows:
#1: SARS-CoV-2 OR COVID-19
#2: metformin OR biguanides
#3: mortality OR severity
#4: #2 OR #3 
#5: #1 AND #4
